Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

PROACT - Pre-Operative Arimidex Compared To Tamoxifen

ClinicalTrials.gov ID: NCT00232661

Public ClinicalTrials.gov record NCT00232661. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Study Comparing ARIMIDEX™ With NOLVADEX™ as Neo-adjuvant and Adjuvant Treatment in Post-menopausal Women With Large Operable (T2 (≥3cm), T3, N0-2, M0) or Potentially-operable, Locally Advanced (T4b, N0-2, M0), ER+ and/or PR+ Breast Cancer.

Study identification

NCT ID
NCT00232661
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
452 participants

Conditions and interventions

Conditions

Interventions

  • ARIMIDEX (anastrazole) Drug
  • NOLVADEX (tamoxifen) Drug

Drug

Eligibility (public fields only)

Age range
60 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jul 31, 2000
Primary completion
Dec 31, 2002
Completion
Nov 30, 2007
Last update posted
Feb 2, 2010

2000 – 2007

United States locations

U.S. sites
13
U.S. states
11
U.S. cities
13
Facility City State ZIP Site status
Research Site Santa Rosa California
Research Site New Britain Connecticut
Research Site Torrington Connecticut
Research Site Springfield Illinois
Research Site Mason City Iowa
Research Site Baton Rouge Louisiana
Research Site Pittsfield Massachusetts
Research Site St Louis Missouri
Research Site Albuquerque New Mexico
Research Site Portland Oregon
Research Site Austin Texas
Research Site Houston Texas
Research Site Olympia Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 66 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00232661, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Feb 2, 2010 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00232661 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →